Abstracts tagged "genomics and rheumatoid arthritis"

Abstract Number: 1595 • 2012 ACR/ARHP Annual Meeting
Genome-Wide Association Study to High -Throughput Cell-Based Phenotypic Screen Identifies Novel Chemical Inhibitors of CD40 Signaling
Gang Li¹, Dorothee Diogo², Di Wu¹, Jim Spoonamore³, Rheumatoid Arthritis Consortium International (RACI)⁴, Eli Stahl⁵, Nicola Tolliday³ and Robert M. Plenge⁶, ¹Division of Rheumatology, Immunology and Allergy and Division of Genetics, Brigham and Women's Hospital, Boston, MA, ²Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ³Broad Institute, Cambridge, MA, ⁴Boston, ⁵Brigham and Women's Hospital, ⁶Division of Rheumatology, Immunology and Allergy and Division of Genetics, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Deriving therapeutic targets from human genetics linked with biological alterations of risk alleles may provide a more successful approach to drug development than traditional…
Abstract Number: 1298 • 2012 ACR/ARHP Annual Meeting
Improvement of Treatment Outcome of Rheumatoid Arthritis with Salazosulfapyridine by Pharmacogenetic Approach
Shunichi Kumagai¹, Yoshiaki Hagiwara², Yoshihide Ichise¹, Sho Sendo³, Nobuhiko Okada¹, Jun Saegusa⁴ and Goh Tsuji⁵, ¹Center of rheumatic diseases, Shinko hospital, Kobe, Japan, ²Department of Evidence-Based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan, ³Center of rheumatic diseases, Shinko Hospital, Kobe, Japan, ⁴Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ⁵Center for Rheumatic Diseases, Shinko Hospital, Kobe, Japan
Background/Purpose: Salazosulfapyridine (SASP) is acetylated in liver by N-acetyltransferase2 (NAT2) in the track of metabolism. Previous studies have shown that genotyping of NAT2 is adequate…
Abstract Number: 995 • 2012 ACR/ARHP Annual Meeting
Genetic Effects of HLA-DRB1, IL4R, and FcγRIIb On Long-Term Treatment Responses in Patients with Early Rheumatoid Arthritis: 78-Week Results of a Phase 4 Study
Alla Skapenko¹, Josef S. Smolen², Arthur Kavanaugh³, Vipin Arora⁴, Hartmut Kupper⁵ and Hendrik Schulze-Koops⁶, ¹Division of Rheumatology and Clinical Immunology, Med. Poliklinik,, University of Munich, Munich, Germany, ²Department of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ³UCSD School of Medicine, La Jolla, CA, ⁴Health Outcomes Research, Abbott, Abbott Park, IL, ⁵Immunology Development, Abbott GmbH and Co. KG, Ludwigshafen, Germany, ⁶University of Munich, Munich, Germany
Background/Purpose: Previous analyses suggested that the HLA-DRB1 shared epitope (SE), and the IL4R V50I and the FcγRIIb I232T single nucleotide polymorphisms (SNPs) affected response to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].